Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression.

ABSTRACT: Cirrhosis, advanced liver disease, affects 2-5 million Americans. While most patients have compensated cirrhosis and may be fairly asymptomatic, many decompensate and experience life-threatening complications such as gastrointestinal bleeding, confusion (hepatic encephalopathy), and ascites, reducing life expectancy from 12 to less than 2 years. Among patients with compensated cirrhosis, identifying patients at high risk of decompensation is critical to optimize care and reduce morbidity and mortality. Therefore, it is important to preferentially direct them towards specialty care which cannot be provided to all patients with cirrhosis. We used discovery Top-down Proteomics (TDP) to identify differentially expressed proteoforms (DEPs) in the plasma of patients with progressive stages of li

SUBMITTER: Forte E 

PROVIDER: S-EPMC11212939 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature